Contact
Please use this form to send email to PR contact of this press release:
TESARO Announces Availability of Zejula™ (Niraparib) for Patients With Recurrent Ovarian Cancer in the U.S.
TO:
Please use this form to send email to PR contact of this press release:
TESARO Announces Availability of Zejula™ (Niraparib) for Patients With Recurrent Ovarian Cancer in the U.S.
TO: